Previous
Previous

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with HR-NBL (HR-NBL1/SIOPEN ph 3 trial)

Next
Next

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Ph 2 Trial